TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  05/25 02:00:00 am EDT
3787.00 JPY   -0.26%
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Projects Decline Next Fiscal
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Named Global Top Employer for Fifth Consecutive Year

01/19/2022 | 07:01pm EDT

−       Achieved Global Recognition And Top Employer Certification In 39 Countries From Top Employers Institute®

−       Recognition Highlights Takeda’s Unwavering Commitment To Its People

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast commitment to create a diverse and inclusive organization that enables its people to thrive.

Established more than 30 years ago, the Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. The survey covers all aspects of HR and employee-centric practices, including: People Strategy, Work Environment, Talent Acquisition, Learning, Well-being, Engagement, Diversity & Inclusion and more.

“It’s an honor to be recognized by Top Employer Institute for the fifth consecutive year as we continue to navigate highly dynamic and evolving workplaces across the globe,” said Lauren Duprey, Chief Human Resources Officer, Takeda. “Over the last decade, Takeda has transformed into a top-tier global biopharmaceutical company dedicated to creating better health for people and a brighter future for the world, and our success – now and into the future – is driven by our people. As we look ahead, we’ll continue building an organization that fosters collaboration and innovation among people from all backgrounds so they can reach their full potential.”

Top Employers Institute CEO David Plink commented, “As we reflect on another demanding year for employers and employees alike, Takeda continues to demonstrate its holistic commitment to employees both at a global and local scale. We congratulate Takeda for another consecutive year receiving global Top Employer certification.”

Takeda excelled globally in the areas of Ethics & Integrity, Values, Business Strategy, Organization and Change, and Employer Branding. Each of the 39 Takeda countries that participated in the Top Employer survey received certification, with two countries receiving certification for the first time. The full list of countries where Takeda was named a Top Employer is below:

  • Africa: Algeria
  • Asia Pacific: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand
  • Europe: Austria, France, Germany, Ireland, Italy, Kazakhstan, Poland, Portugal, Romania, Russia, Serbia, Spain, Switzerland, Turkey, UK and Ukraine
  • Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico and Peru
  • Middle East: Israel, Saudi Arabia, and United Arab Emirates
  • North America: United States

To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


© Business Wire 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project..
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022
CI
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022
CI
05/11Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021
MT
05/11Takeda Pharmaceutical Posted Fourth-Quarter Net Loss
DJ
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
05/11Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F..
CI
05/11Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 27 429 M 27 429 M
Net income 2022 239 B 1 878 M 1 878 M
Net Debt 2022 3 299 B 25 923 M 25 923 M
P/E ratio 2022 24,7x
Yield 2022 4,75%
Capitalization 5 845 B 45 938 M 45 938 M
EV / Sales 2022 2,62x
EV / Sales 2023 2,41x
Nbr of Employees 47 099
Free-Float 97,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 787,00 JPY
Average target price 4 402,67 JPY
Spread / Average Target 16,3%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.04%46 319
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494